Veraxa Biotech AG (VRXA)
NASDAQ: VRXA · Real-Time Price · USD
1.530
+0.150 (10.87%)
At close: Sep 3, 2026, 4:00 PM EDT
1.582
+0.052 (3.39%)
Pre-market: Sep 4, 2026, 7:54 AM EDT
Veraxa Biotech AG Revenue
In the year 2025, Veraxa Biotech AG had annual revenue of 23.43K CHF.
Revenue (ttm)
23.43K CHF
Revenue Growth
n/a
P/S Ratio
7,323.36
Revenue / Employee
n/a
Employees
n/a
Market Cap
216.35M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 23.43K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
VRXA News
- 1 hour ago - Veraxa Biotech appoints Raju Willener as CFO - TheFly
- 1 hour ago - VERAXA Biotech Appoints Raju Willener as Chief Financial Officer - GlobeNewsWire
- 11 days ago - Veraxa Biotech, Secarna announce initial results from AOC alliance - TheFly
- 5 weeks ago - VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates - GlobeNewsWire
- 5 weeks ago - Veraxa Biotech advances VXA-222 following milestone in OmniAb pact - TheFly
- 5 weeks ago - VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb - GlobeNewsWire
- 5 weeks ago - VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth - GlobeNewsWire
- 6 weeks ago - Veraxa Biotech appoints Christoph Erkel as chief scientific officer - TheFly